Big Moving Stock chart patterns and volume.

Nasdaq: GOOG BIIB NFLX AMZN IBB TSLA ALXN SLXP AMGN COST BMRN WYNN AAPL VRTX CELG GMCR GILD SWKS SBUX
Nyse:
New Highs: ORLY LMT RCPT PANW CI WBC UNH SJM RH COL KRFT MSG TGT MKC RHT KSS AMBA CNC TJX KMX

The Hot Industries

Health Care Plans 3
Processed & Packaged Goods 2
Aerospace/Defense Products & Services 2

The Hot Sectors

Services 6
Consumer Goods 4
Healthcare 4

Social Buzz

SPPI is headed higher?
Watchlist:

SPPI Stock ChartSimilar Stocks: SGEN BIIB TEVA ABPI SGNT ATNM CELG


SPPI
Analyze

Sector:

Healthcare
Daily

Industry:

Biotechnology
Weekly

Employees:

N/A
Monthly

Website:

http://www.sppirx.com

SPPI Spectrum Pharmaceuticals, Inc.

Spectrum Pharmaceuticals, Inc., a biotechnology company, develops and commercializes oncology and hematology drug products. The company’s commercialized drug products include FUSILEV for the treatment of patients with metastatic colorectal cancer, rescue after high-dose methotrexate therapy in osteosarcoma, and to diminish the toxicity and counteract the effects of impaired methotrexate elimination and of inadvertent overdosage of folic acid antagonists; FOLOTYN, a folate analogue metabolic inhibitor for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma; ZEVALIN injection for intravenous use as a prescription medication; and MARQIBO, a sphingomyelin/cholesterol liposome-encapsulated formulation of the anticancer drug vincristine for the treatment of adult patients with Philadelphia chromosome-negative acute lymphoblastic leukemia. It also develops BELEODAQ for the treatment of various hematological and solid tumors; Captisol-enabled MELPHALAN, an intravenous formulation of MELPHALAN for clinicians and patients in the multiple myeloma transplant setting; APAZIQUONE to treat non-muscle invasive bladder cancer; and SPI-2012 for the treatment of chemotherapy-induced neutropenia. The company sells its drugs through a direct sales force in the United States; and through distributors in Europe and Japan. It has licensing and development agreement with Cell Therapeutics, Inc.; license agreement with Merck & Cie AG and Cydex Pharmaceuticals, Inc.; development and commercialization collaboration agreement with Allergan; collaboration agreement with Nippon Kayaku Co., Ltd.; licensing and collaboration agreement with TopoTarget A/S; and co-development and commercialization agreement with Hanmi Pharmaceutical Company. The company was formerly known as NeoTherapeutics, Inc. and changed its name to Spectrum Pharmaceuticals, Inc. in December 2002. Spectrum Pharmaceuticals, Inc. was founded in 1987 and is headquartered in Henderson, Nevada.

favicon

InPlay from Briefing.com

30 Mar 2015, 4:16 pmInPlay from Briefing.com
favicon

Technical Pulse on Biotech Stocks -- Geron, Lexicon Pharma, XOMA Corp., Spectrum Pharma, and BioLine RX

23 Mar 2015, 7:29 amLONDON, March 23, 2015 /PRNewswire/ -- Editor Note: For more information about this release, please scroll to bottom. Investor-Edge has initiated coverage on the following equities: Geron Corporation (NASDAQ: GERN), Lexicon Pharmaceuticals Inc. (NASDAQ: LXRX), XOMA Corporation (NASDAQ:...
favicon

ETF Preview: ETFs Lower, Futures Rise as Rate-Increase Fears Fade; Consumer-Sentiment Data Still Ahead

13 Mar 2015, 8:32 amETF Preview: ETFs Lower, Futures Rise as Rate-Increase Fears Fade; Consumer-Sentiment Data Still Ahead
favicon

Health Care Sector Update for 03/13/2015: SPPI, ZSPH, GSK

13 Mar 2015, 7:01 amHealth Care Sector Update for 03/13/2015: SPPI, ZSPH, GSK
favicon

Spectrum Pharma reports 4Q loss

13 Mar 2015, 5:18 amOn a per-share basis, the Henderson, Nevada-based company said it had a loss of 5 cents. Earnings, adjusted for amortization costs and stock option expense, were 9 cents per share. The results exceeded ...
favicon

Spectrum Pharmaceuticals Reports Robust Clinical Data and Strong 2014 Financial Results

13 Mar 2015, 5:00 amSpectrum Pharmaceuticals, Inc. , a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and onc
favicon

Pre-Market Earnings Report for March 13, 2015 : BKE, ANN, HIBB, BTG, EBIX, RGEN, STON, PETX, TA, SPPI, CTRN, VISI

12 Mar 2015, 2:16 pmPre-Market Earnings Report for March 13, 2015 : BKE, ANN, HIBB, BTG, EBIX, RGEN, STON, PETX, TA, SPPI, CTRN, VISI
favicon

Spectrum Pharmaceuticals' CE-melphalan Under Review - Analyst Blog

10 Mar 2015, 3:21 pmSpectrum Pharmaceuticals' (SPPI) NDA for Captisol-enabled melphalan was accepted by the FDA for review.
favicon

ACRX Plunges On Zalviso News, CTIC Persists, HTBX On Fire, PIP Cuts Head Count

10 Mar 2015, 5:46 amACRX Plunges On Zalviso News, CTIC Persists, HTBX On Fire, PIP Cuts Head Count
favicon

Spectrum Pharmaceuticals (SPPI) Stock Plunges to One-Year Low on Court's Fusilev Patent Ruling

9 Mar 2015, 4:48 amNEW YORK (TheStreet) -- Shares of Spectrum Pharmaceuticals  plunged more than 20% to a 52-week low of $5.65 on Monday after a U.S. District Court ruled Friday that patent claims of its Fusilev cancer drug are invalid. The U.S. District Court for the District of Nevada ruled Friday that claims 1 and 2 of Spectrum's '829 patent that covers Fusilev are invalid. Spectrum had previously sued generic ...